Investing.com -- Spire Healthcare Group plc (LSE:SPI) announced Wednesday that its full-year adjusted EBITDA for 2025 is expected to be around the bottom end of its guidance range of £270 million to £285 million, despite positive trading in recent months.
The UK-based independent healthcare provider reported 3.6% year-over-year revenue growth for the four-month period from July to October 2025, following 4.9% growth in the first half of the year.
The company’s transformation program is on track to deliver £30 million in new savings during the year, including an additional £10 million identified earlier in 2025 to offset half the costs from increases in National Insurance and National Minimum Wage.
Spire noted that while self-pay trends have continued to improve and private medical insurance (PMI) trends remain broadly unchanged since the first half, these positive factors have not been sufficient to counter a recent slowdown in NHS commissioning activity due to Integrated Care Board budgetary restrictions.
Looking ahead to fiscal year 2026, Spire expects adjusted EBITDA to be "broadly in line or slightly ahead of 2025," citing continued improvement in self-pay and PMI trends as its Patient Support Centres reach operational maturity. The company plans to deliver a further £30 million in new savings next year.
Spire also announced an 18-month extension to its existing banking facilities of £425 million, which now mature in August 2028. The facility comprises a £325 million term loan and a £100 million revolving credit facility.
The company confirmed it is evaluating actions to drive shareholder value, including discussions with various parties about potential options such as a company sale, value generation from its hospital property estate, and increased focus on private payors.
Spire entered an "offer period" under the Takeover Code following its September 19 announcement, but noted there is no certainty that any offer will be made.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.








